Liberty Global Ventures and Motorola Mobility Ventures both scored exits from the media content monetisation service in an acquisition by TV Time.
Takeda is set to emerge with almost 26% of Phathom Pharmaceuticals, which has licensed one of its gastrointestinal disease drugs, and which is targeting $158m.
ProMedica and Pacira are both in line for exits after surgical implant producer Tela Bio filed for an initial public offering.
The consumer engagement tool developer has been acquired by Appier after raising $3.2m from investors including Digital Garage four years earlier.
Louken Group is exiting CombineSell in an acquisition by Shopmatic, having backed the e-commerce management platform developer at seed stage.
SoftBank Vision Fund-backed immunology therapy developer Vir will float at the bottom of its range, having raised in excess of $820m in VC funding in roughly three years.
Online real estate marketplace Fangdd has filed for a $150m initial public offering that would allow Shanying International to exit.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
